

# SB1934



## 98TH GENERAL ASSEMBLY

### State of Illinois

2013 and 2014

SB1934

Introduced 2/15/2013, by Sen. Antonio Muñoz - Iris Y. Martinez  
- Pamela J. Althoff - Melinda Bush

#### SYNOPSIS AS INTRODUCED:

225 ILCS 85/19.5 new

Amends the Pharmacy Practice Act. Provides that a pharmacist may substitute a prescription biosimilar product for a prescribed biological product under certain circumstances. Provides that the Board shall adopt rules for compliance with these provisions. Effective immediately.

LRB098 10574 MGM 40827 b

FISCAL NOTE ACT  
MAY APPLY

A BILL FOR

1 AN ACT concerning regulation.

2 **Be it enacted by the People of the State of Illinois,**  
3 **represented in the General Assembly:**

4 Section 5. The Pharmacy Practice Act is amended by adding  
5 Section 19.5 as follows:

6 (225 ILCS 85/19.5 new)

7 Sec. 19.5. Biosimilars products.

8 (a) For the purposes of this Section:

9 "Biological product", "biosimilar", and "interchangeable"  
10 have the same meanings as under Section 351 of the Public  
11 Health Service Act (42 U.S.C. 262).

12 "Prescription", with respect to a biological product,  
13 means a product that is subject to Section 503 (b) of the  
14 Federal, Food, Drug, and Cosmetic Act (21 U.S.C. 353(b)).

15 (b) A pharmacist may substitute a prescription biosimilar  
16 product for a prescribed biological product only if:

17 (1) the biosimilar product has been determined by the  
18 United States Food and Drug Administration to be  
19 interchangeable with the prescribed biological product;

20 (2) the prescribing physician does not designate  
21 orally, in writing, or electronically that substitution is  
22 prohibited in a manner inconsistent with Section 25 of this  
23 Act;

1           (3) the pharmacy informs the patient of the  
2           substitution;

3           (4) the pharmacist informs the prescriber within 5  
4           business days of the substitution, including the name and  
5           manufacturer of the interchangeable biosimilar dispensed;

6           (5) the pharmacy retains a written record of the  
7           interchangeable biosimilar substitution for a period of no  
8           less than 5 years.

9           (c) The Board shall adopt rules for compliance with this  
10          Section.

11

12           Section 99. Effective date. This Act takes effect upon  
13          becoming law.